Lakefront Biotherapeutics NV (AMS:LKFT)
25.30
+0.02 (0.08%)
Aug 27, 2026, 5:35 PM CET
Lakefront Biotherapeutics NV Employees
Lakefront Biotherapeutics NV had 452 employees as of December 31, 2025. The number of employees decreased by 252 or -35.80% compared to the previous year.
Employees
452
Change
-252
Growth
-35.80%
Revenue / Employee
€5,053,949
Profits / Employee
€3,044,061
Market Cap
1.64B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 452 | -252 | -35.80% |
| Jun 30, 2025 | 558 | - | - |
| Dec 31, 2024 | 704 | -419 | -37.31% |
| Dec 31, 2023 | 1,123 | -215 | -16.07% |
| Dec 31, 2022 | 1,338 | 29 | 2.22% |
| Sep 30, 2022 | 1,357 | 38 | 2.88% |
| Mar 31, 2022 | 1,305 | -23 | -1.73% |
| Dec 31, 2021 | 1,309 | -180 | -12.09% |
| Sep 30, 2021 | 1,319 | -88 | -6.25% |
| Jun 30, 2021 | 1,397 | 267 | 23.63% |
| Mar 31, 2021 | 1,328 | 198 | 17.52% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Signify | 25,866 |
| Havas | 22,960 |
| Fugro | 10,000 |
| Basic-Fit | 7,906 |
| Koninklijke Heijmans | 6,361 |
| TKH Group | 6,151 |
| AMG Critical Materials | 3,500 |
| Corbion | 2,363 |
Lakefront Biotherapeutics NV News
- 2 days ago - Acquisition of Own Shares - GlobeNewsWire
- 3 days ago - Lakefront Biotherapeutics granted orphan drug designation for gamgertamig - TheFly
- 3 days ago - U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus - GlobeNewsWire
- 3 days ago - Lakefront Receives Transparency Notification from Bank of America - GlobeNewsWire
- 16 days ago - Lakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley - TheFly
- 16 days ago - Lakefront Biotherapeutics NV Earnings release: Q2 2026 - Filings
- 16 days ago - Lakefront Biotherapeutics NV Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi - GlobeNewsWire